Standard: this guide onlyAll-Access Lifetime: all 45 guides + downloadsEducational content only
PE-22-28 Guide: Available Now
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
PE-22-28 at a glance
What it is
Synthetic 7-amino-acid peptide (residues 22-28 of spadin), a selective TREK-1 (KCNK2) potassium-channel inhibitor
Researched for
Antidepressant-like activity and hippocampal neurogenesis in rodent models
Commonly reported range
50-200 mcg per administration (community-reported; no human dosing established)
Route reported
Subcutaneous injection (some community reports of intranasal use)
Reported frequency
Once daily
Reported cycle
Approximately 8-16 weeks in community protocols
Plasma half-life
Human half-life not established; rodent duration of action reported ~23 hours
Regulatory status
Not FDA-approved; investigational/research-only; WADA-prohibited (S0, non-approved substances)
Reported ranges from research/community — examples, not recommendations.
What it is / mechanism
PE-22-28 is a synthetic seven-residue peptide corresponding to residues 22-28 of spadin, a naturally occurring peptide cleaved from the propeptide of sortilin. Its reported primary action is selective inhibition of the TREK-1 (KCNK2) two-pore-domain potassium channel, with a reported IC50 near 0.12 nM in laboratory assays, described as roughly 300-fold more potent than parent spadin. TREK-1 blockade is proposed to increase the firing of serotonergic neurons in the dorsal raphe nucleus and to enhance downstream signaling associated with CREB activation and BDNF. In rodent studies this has been linked to increased hippocampal neurogenesis and synaptogenesis. These are reported mechanistic findings from preclinical research, not established effects in humans.
Researched effects
In rodent behavioral models such as the forced swim test and novelty-suppressed feeding paradigm, PE-22-28 has been reported to produce antidepressant-like effects, in some cases described as emerging within days rather than the weeks typical of conventional antidepressants. Additional preclinical reports describe reduced apoptotic cell death, increased hippocampal neurogenesis, and improved outcomes in ischemia and stroke models. These are research findings from animal studies, not guaranteed outcomes; there is no confirmed human efficacy for any indication.
Evidence & regulatory status
Evidence: Effects are drawn almost entirely from rodent behavioral and neurogenesis studies; as of 2026, PubMed searches return no published human clinical trials under the PE-22-28 name.
Regulatory: PE-22-28 is not FDA-approved for any indication, is not on FDA bulk-compounding substance lists, and is prohibited by WADA under category S0 (non-approved substances).
Research-use: PE-22-28 is sold and handled as a research chemical for laboratory and educational purposes only; any human use occurs outside regulatory oversight.
Dosage — reported ranges (overview)
There is no established or approved human dose for PE-22-28. Published preclinical work used weight-based rodent dosing (for example, roughly 3.2-4.0 mcg/kg intraperitoneally, or about 1.0 mg/kg by oral gavage). In community and vendor materials, subcutaneous ranges of approximately 50-200 mcg once daily over 8-16 week cycles are commonly reported, often starting low (around 50 mcg) and titrating upward. The figures below are examples of what is reported in the research-chemical community, not a recommendation or a personal dose.
The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.
Reconstitution — bac-water math
Reconstitution is concentration math only, not a personal dose. A lyophilized peptide vial is mixed with bacteriostatic water; the amount of water sets the concentration. For a compound dosed in micrograms, concentration in mcg/mL = (vial mg x 1000) / water mL, and the units drawn on a U-100 insulin syringe = dose in mcg / concentration in mcg/mL x 100 (where 100 units = 1 mL). Worked example: a 10 mg vial reconstituted with 2 mL of water gives 5,000 mcg/mL, so a 100 mcg example dose = 100 / 5000 x 100 = 2 units on a U-100 syringe.
Bac water added
Concentration
50 mcg (low example)
200 mcg (high example)
1 mL
10,000 mcg/mL (10 mg/mL)
0.5 units
2 units
2 mL
5,000 mcg/mL (5 mg/mL)
1 unit
4 units
3 mL
3,333 mcg/mL (3.33 mg/mL)
1.5 units
6 units
This is concentration math, not a dose recommendation.
Pre-fills example values. Every field remains editable.
The amount printed on the vial or listed on a product page.
mL
Liquid volume used for the concentration calculation.
The mass amount to convert into liquid volume for this math example.
4. Insulin syringe size
Your result
Syringe-unit reading
10 units
= 0.1 mL · 250 mcg target amount
Concentration
2.5mg/mL
Per insulin unit
25mcg
Portions per vial
20
Volume
0.1mL
This calculator is an educational tool for laboratory and research math only. The peptides referenced are research compounds not intended for human or veterinary use, and example values are not medical advice or personal-use instructions. Follow applicable research protocols and regulations.
How the calculator works
Concentration
peptide ÷ liquid
Total peptide divided by liquid volume gives the concentration per mL.
Volume
target ÷ concentration
The target mass divided by concentration gives the liquid volume.
Syringe units
volume × 100
For insulin units, 100 units equals 1 mL, so mL is multiplied by 100.
Worked example: A 5 mg vial plus 2 mL liquid creates a 2.5 mg/mL concentration. A 250 mcg target amount equals 0.1 mL, or 10 insulin units. The vial contains 20 such portions.
Frequently asked questions
How much bacteriostatic water should I enter?+
There is no single calculator-default amount. The liquid volume controls concentration: more liquid creates a less concentrated solution and a larger volume reading for the same target amount; less liquid creates a more concentrated solution and a smaller volume reading.
How do insulin syringe units relate to mL?+
For this math tool, 100 insulin units equals 1 mL, and 1 unit equals 0.01 mL. The 0.3 mL, 0.5 mL, and 1.0 mL options change capacity, not the unit-to-mL relationship.
What is the difference between mg, mcg, and units?+
Milligrams and micrograms measure peptide mass: 1 mg = 1,000 mcg. Syringe units measure liquid volume. Reconstitution math connects mass and volume by using concentration.
Does changing the liquid volume change the total peptide in the vial?+
No. The total peptide amount entered for the vial remains fixed. Changing the liquid volume only changes concentration and the resulting volume shown by the calculator.
Injection / administration basics
In community reports, PE-22-28 is most often prepared as a subcutaneous injection using a U-100 insulin syringe, with some users describing intranasal administration instead. General handling practices reported include reconstituting gently down the vial wall rather than directly onto the powder, swabbing the vial stopper and injection site, and rotating sites when injecting subcutaneously. This describes reported handling practices, not medical instructions or a personal protocol.
Half-life & frequency rationale
A validated human plasma half-life for PE-22-28 has not been established, as no human pharmacokinetic studies have been published. Preclinical work reports a duration of action of approximately 23 hours (compared with roughly 7 hours for parent spadin), reflecting improved resistance to enzymatic degradation, which is the basis for community once-daily dosing schedules.
Side effects, safety & contraindications
Human safety data for PE-22-28 are essentially absent, so its side-effect profile in people is unknown. Preclinical literature raises a theoretical mechanistic concern: because TREK-1 loss worsened outcomes in some rodent stroke models, chronic broad TREK-1 blockade could plausibly be unfavorable in cerebrovascular contexts. As with other injectable research peptides, injection-site reactions and responses to non-sterile preparation are general possibilities. The limited human data here means potential risks are not well characterized.
Stacking — overview
PE-22-28 is most often discussed within the nootropic and mood-research space, where community reports pair it with other neuro-focused peptides rather than with growth or repair compounds. Any combination compounds unknowns, since none of these pairings have human safety or efficacy data. The stacks below reflect commonly reported community pairings for educational context, not recommendations.
Cognitive/mood stack
PE-22-28 + Semax or Selank (nootropic research pairing)
Storage & handling
Lyophilized (powder): store sealed and protected from light, refrigerated at 2-8 C for near-term use or frozen around -20 C for longer storage.
Reconstituted (in bacteriostatic water): refrigerate at 2-8 C, keep away from light, and use within roughly 4 weeks.
References
Key sources include preclinical publications on spadin and TREK-1 channel inhibition (Mazella and colleagues), WADA prohibited-list documentation, and research-vendor and peptide-database summaries reviewed in 2026; none constitute human clinical validation.
Related peptide guides
Continue exploring related educational guide topics in the Medibact library.
Quick answers about guide scope, access, and educational use context.
What is PE-22-28?
PE-22-28 is a synthetic seven-amino-acid peptide derived from residues 22-28 of spadin. It is studied in preclinical research as a highly selective inhibitor of the TREK-1 potassium channel, with reported antidepressant-like and neurogenic activity in rodents. It is a research compound, not an approved medicine.
Is PE-22-28 approved or proven in humans?
No. PE-22-28 is not FDA-approved for any indication, and as of 2026 there are no published human clinical trials under its name. All efficacy evidence comes from animal studies, and human safety is not characterized.
How is PE-22-28 dosed in research reports?
There is no established human dose. Preclinical studies used weight-based rodent dosing, while community and vendor materials commonly report about 50-200 mcg subcutaneously once daily over 8-16 week cycles. These are reported examples, not a recommendation or a personal dose.
How is PE-22-28 reconstituted?
A lyophilized vial is mixed with bacteriostatic water, and the water volume sets the concentration: mcg/mL = (vial mg x 1000) / water mL. For a 10 mg vial with 2 mL water you get 5,000 mcg/mL, so a 100 mcg example equals 2 units on a U-100 insulin syringe. This is concentration math only.
Is PE-22-28 banned in sport?
Yes. As a non-approved investigational substance, PE-22-28 falls under WADA prohibited category S0, which covers substances not approved for human therapeutic use. Athletes subject to anti-doping rules should treat it as prohibited.
Compliance and trust notes
Educational content only; no personalized health or outcome claims.
No personalized use recommendation outputs.
Use this material for general learning and research-context literacy.
Educational use only — not medical advice. This guide summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.
